Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148823 | 1.00 | LOXL2 (0.60) | LOXL2IDO1DPP4DPP7TSHR | |
| Hydrochloric Acid SCHEMBL9355954 | 0.98 | LOXL2 (0.58) | LOXL2IDO1DPP4DPP7TSHR | |
| Acetic Acid SCHEMBL9334210 | 0.91 | LOXL2 (0.50) | LOXL2IDO1DPP4DPP7TSHR | |
| SCHEMBL10904353 | 0.88 | LOXL2 (0.47) | LOXL2IDO1DPP4DPP7TSHR | |
| SCHEMBL10904351 | 0.88 | LOXL2 (0.47) | LOXL2IDO1DPP4DPP7TSHR | |
| Hydrochloric Acid SCHEMBL10902175 | 0.87 | DPP4 (0.46) | LOXL2IDO1DPP4DPP7TSHR | |
| SCHEMBL1176909 | 0.85 | TSHR (0.56) | LOXL2IDO1DPP4DPP7TSHR | |
| SCHEMBL334475 | 0.85 | TSHR (0.56) | LOXL2IDO1DPP4DPP7TSHR | |
| SCHEMBL8186292 | 0.85 | TSHR (0.56) | LOXL2IDO1DPP4DPP7TSHR | |
| SCHEMBL15994105 | 0.84 | EPHX1 (0.61) | LOXL2IDO1DPP4DPP7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3318555-B1 | BIFUNCTIONAL CHELATING AGENTS | BWXT MEDICAL LTD (CA) | 2023-08-16 | — | — | EP | disclosed |
| CN-116577508-A | Monoclonal antibody Ab614 fluorescent complex and application thereof | 江苏博华医药科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-11691997-B2 | Macrocycles | LUMIPHORE, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-114409578-B | Preparation method of multi-aptamer molecule | 安源基因科技(上海)有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-114441749-B | Application of novel multi-element aptamer molecules in magnetic bead immunochemiluminescence AFP | 安源基因科技(上海)有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-114441749-A | Application of novel multi-element aptamer molecule in magnetic bead immunochemistry luminous AFP | 安源基因科技(上海)有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-114409578-A | Preparation method of novel multi-aptamer molecule | 安源基因科技(上海)有限公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3318555-A1 | BIFUNCTIONAL CHELATING AGENTS | Nordion (Canada) Inc. (CA) | 2018-05-09 | — | — | EP | disclosed |
| US-9849196-B2 | Methods and compositions for altering photophysical properties of fluorophores via proximal quenching | CORNELL UNIVERSITY (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2536691-B1 | BIFUNCTIONAL CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2017-11-22 | — | — | EP | disclosed |
| US-5318772-A | Polyaminemethylenephosphonic acids of diethylenediamine, norbornanediamne, 1,4,7,10-tetraazacyclododecane, 3,6,9,15-tetraazabicyclo(9.3.1)pentadecatriene or 1,4,7-triazanonane and a suitable vehicle | THE DOW CHEMICAL COMPANY (US) | 1994-06-07 | — | — | US | disclosed |
| EP-0344724-B1 | METAL RADIONUCLIDE CHELATING COMPOUNDS FOR IMPROVED CHELATION KINETICS | NEORX CORPORATION (US) | 1993-08-11 | — | — | EP | disclosed |
| WO-1993011741-A1 | ORAL COMPOSITIONS FOR INHIBITING PLAQUE AND CALCULUS FORMATION | THE DOW CHEMICAL COMPANY (US) | 1993-06-24 | — | — | WO | disclosed |
| US-5075099-A | Metal radionuclide chelating compounds for improved chelation kinetics | NEORX CORPORATION (US) | 1991-12-24 | — | — | US | disclosed |
| US-5006643-A | Reacting aminofunctional chelates with thiophosgene | THE DOW CHEMICAL COMPANY (US) | 1991-04-09 | — | — | US | disclosed |
| US-4988496-A | Metal radionuclide chelating compounds for improved chelation kinetics | NEORX CORPORATION (US) | 1991-01-29 | — | — | US | disclosed |
| WO-1990007342-A1 | PROCESS FOR PREPARING ISOTHIOCYANATO FUNCTIONALIZED METAL COMPLEXES | THE DOW CHEMICAL COMPANY (US) | 1990-07-12 | — | — | WO | disclosed |
| EP-0374947-A1 | Process for preparing isothiocyanato functionalized metal complexes | THE DOW CHEMICAL COMPANY (US) | 1990-06-27 | — | — | EP | disclosed |
| US-4923985-A | Process for synthesizing macrocyclic chelates | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 1990-05-08 | — | — | US | disclosed |
| EP-0344724-A2 | Metal radionuclide chelating compounds for improved chelation kinetics | NEORX CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691997-B2 | Macrocycles | HCCS, ABCB7, AURKAIP1 | LOXL2 4405/4885IDO1 2537/4885DPP4 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.